中文名 | N-(4-哌啶基)-4-(2,6-二氯苯甲酰基氨基)-1H-吡唑-3-甲酰胺盐酸盐 |
英文名 | N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide hydrochloride |
别名 | AT 7519 盐酸盐 N-(4-哌啶基)-4-(2,6-二氯苄氨基)-1H-吡唑-3-羧胺盐酸盐 N-(4-哌啶基)-4-(2,6-二氯苄氨基)-1H-吡唑-3-羧氨盐酸盐 N-(4-哌啶基)-4-(2,6-二氯苯甲酰基氨基)-1H-吡唑-3-甲酰胺盐酸盐 |
英文别名 | CS-266 AT7519 AT 7519 AT-7519 AT-7519 AT-7519(HCl) AT 7519 HYDROCHLORIDE AT-7519 HYDROCHLORIDE AT7519 (Hydrochloride) 4-(2,6-Dichlorobenzamido)-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide HCl N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide Hcl N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide Hcl N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide hydrochloride |
CAS | 902135-91-5 |
化学式 | C16H18Cl3N5O2 |
分子量 | 418.7 |
InChI | InChI=1S/C16H17Cl2N5O2.ClH/c17-10-2-1-3-11(18)13(10)15(24)22-12-8-20-23-14(12)16(25)21-9-4-6-19-7-5-9;/h1-3,8-9,19H,4-7H2,(H,20,23)(H,21,25)(H,22,24);1H |
存储条件 | -20℃ |
体外研究 | AT7519是一种ATP竞争性CDK抑制剂,对CDK1的K i 值为38 nM。AT7519对所有非CDK激酶没有活性,除了GSK3β (IC50 = 89 nM)。AT7519在各种人肿瘤细胞系中表现出有效的抗增殖活性,IC50值范围为40 nM(对MCF-7)到940 nM(对SW620),与对CDK1和CDK2的抑制一致。 AT7519在多发性骨髓瘤(MM)细胞系中诱导剂量依赖性细胞毒性,在48小时,IC50值范围为0.5到2 μM,最敏感的细胞系为MM.1S (0.5 μM)和U266 (0.5 μM),最耐药的是MM.1R (>2 μM)。它在外周血单核细胞(PBMNC)中不会诱导细胞毒性。AT7519部分抑制IL6和IGF-1诱导的增殖优势,以及骨髓基质细胞(BMSCs)的保护作用。AT7519在丝氨酸2和丝氨酸5位点诱导快速的RNA pol II CTD去磷酸化,并导致转录的抑制,部分有助于AT7519诱导的MM细胞的细胞毒性。AT7519通过下调GSK-3β磷酸化诱导GSK-3β的活化,这也有助于AT7519诱导的独立于转录抑制的细胞凋亡。 |
体内研究 | 在HCT116和HT29结肠癌异种移植物模型中,AT7519 (9.1 mg/kg)每天两次给药引起早期和晚期皮下注射的肿瘤退化。在人MM异种移植小鼠模型中,AT7519治疗(15 mg/kg)抑制肿瘤生长,并延长小鼠平均整体存活期,这与增加的caspase 3活化相关。 |
参考资料 展开查看 | 1: Komiyama T, Kihara H, Hirose K, Yoshimoto R, Shigematsu H. AT-1015, a novel serotonin2A receptor antagonist, improves resaturation of exercised ischemic muscle in hypercholesterolemic rabbits. J Vasc Surg. 2004 Mar;39(3):661-7. PubMed PMID: 14981464. 2: Rashid M, Watanabe M, Nakazawa M, Nagatomo T. AT-1015, a newly synthesized 5-HT2 receptor antagonist, dissociates slowly from the 5-HT2 receptor sites in rabbit cerebral cortex membrane. J Pharm Pharmacol. 2002 Aug;54(8):1123-8. PubMed PMID: 12195828. 3: Rashid M, Watanabe M, Nakazawa M, Nakamura T, Hattori K, Nagatom T. Assessment of affinity and dissociation ability of a newly synthesized 5-HT2 antagonist, AT-101 5: comparison with other 5-HT2 antagonists. Jpn J Pharmacol. 2001 Nov;87(3):189-94. PubMed PMID: 11885967. 4: Kihara H, Koganei H, Hirose K, Yamamoto H, Yoshimoto R. Antithrombotic activity of AT-1015, a potent 5-HT(2A) receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time. Eur J Pharmacol. 2001 Dec 21;433(2-3):157-62. PubMed PMID: 11755147. 5: Kihara H, Hirose K, Koganei H, Sasaki N, Yamamoto H, Kimura A, Nishimori T, Shoji M, Yoshimoto R. AT-1015, a novel serotonin (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2A receptors and prevents the laurate-induced peripheral vascular lesion in rats. J Cardiovasc Pharmacol. 2000 Apr;35(4):523-30. PubMed PMID: 10774780. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.616 ml | 13.081 ml | 26.162 ml |
5 mM | 0.523 ml | 2.616 ml | 5.232 ml |
10 mM | 0.262 ml | 1.308 ml | 2.616 ml |
5 mM | 0.052 ml | 0.262 ml | 0.523 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!